Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Plasmablastic Lymphoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 42Rituximab 40Vincristine 31Doxorubicin 29Prednisone 28Etoposide 27Filgrastim 22Peripheral Blood Stem Cell Transplantation 16Radiotherapy 12Ifosfamide 12Cytarabine 12Magnetic Resonance Spectroscopy 10Methotrexate 9Lenalidomide 8Cyclosporine 8Bortezomib 8fludarabine phosphate 7Vorinostat 7Specimen Handling 7Cisplatin 7Carboplatin 7tanespimycin 6ibrutinib 6Melphalan 6Gemcitabine 6Biopsy 6oblimersen 5alvocidib 5aldesleukin 5Oxaliplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × varlilumab × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡